Abstract
Health technology assessment (HTA) bodies increasingly acknowledge the value of real-world evidence (RWE) for decision-making, with the UK’s National Institute for Health and Care Excellence (NICE) and the French Haute Autorité de Santé (HAS) having formalised their requirements. Alignment of HTA body RWE guidelines is key to designing studies that are transferable between countries in specific cases, such as rare diseases. This study reviewed RWE guidelines from NICE and HAS to assess the feasibility of conducting a single RWE study acceptable to both HTA bodies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
